AAA
ACHL

Affinity Asset Advisors’s Achilles Therapeutics ACHL Stock Holding History

Affinity Asset Advisors’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$779K – 76
2021
Q3 		$779K Buy
100,000
+20,000
+25% +$132K 0.2% 62
2021
Q2 		$783K Buy
80,000
+55,000
+220% +$746K 0.28% 59
2021
Q1 		$414K Buy
+25,000
New +$414K 0.14% 67

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Affinity Asset Advisors's ACHL Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Achilles Therapeutics (ACHL) in Q4 2021, closing a stake of 100,000 shares — an estimated $779K sold.

Affinity Asset Advisors first reported a position in ACHL in Q1 2021 and held it in 3 quarters. The position peaked at $783K in Q2 2021. 30 funds tracked by Wall St. Rank hold ACHL as of Q4 2021.

  • Affinity Asset Advisors reported no remaining Achilles Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 100,000 Achilles Therapeutics shares in Q4 2021, an estimated $779K.
  • Affinity Asset Advisors first reported a position in Achilles Therapeutics in Q1 2021 and held it in 3 quarters.
  • Affinity Asset Advisors's Achilles Therapeutics position peaked at $783K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.